Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.64 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.64 |
| ▸ | KMO | O15229 | 2/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929320 | 0.85 | HIF1A (0.55) | ALDH1A1P4HA1MIFP4HTMKDM4E | |
| SCHEMBL71034 | 0.85 | HIF1A (0.55) | ALDH1A1P4HA1MIFP4HTMKDM4E | |
| SCHEMBL13731115 | 0.84 | P4HTM (0.64) | ALDH1A1CYP1A2CYP3A4P4HA1MIF | |
| SCHEMBL4768271 | 0.84 | MKNK1 (0.65) | MKNK1MKNK2CYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL31228498 | 0.84 | MKNK1 (0.65) | MKNK1MKNK2CYP2A6ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28470042 | 0.83 | HIF1A (0.54) | ALDH1A1P4HA1MIFP4HTMKDM4E | |
| SCHEMBL31512829 | 0.81 | P4HTM (0.52) | MKNK1MKNK2ALDH1A1HCAR2P4HA1 | |
| Ethylene SCHEMBL29031104 | 0.81 | HIF1A (0.53) | ALDH1A1P4HA1MIFP4HTMKDM4E | |
| SCHEMBL13188221 | 0.81 | KMO (0.63) | MKNK1MKNK2KMOCYP2A6ALDH1A1 | |
| SCHEMBL20448087 | 0.81 | KMO (0.67) | MKNK1MKNK2KMOCYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| EP-3056485-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2018-05-09 | — | — | EP | disclosed |
| EP-2699561-B1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORP (FI) | 2015-06-03 | — | — | EP | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| US-8921378-B2 | Androgen receptor modulating carboxamides | ORION CORPORATION (FI) | 2014-12-30 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| EP-2699561-A1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | Orion Corporation (FI) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143599-A1 | ANDROGEN RECEPTOR MODULATING CARBOXAMIDES | ORION CORPORATION (FI) | 2012-10-26 | — | — | WO | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MKNK1 2453/4885MKNK2 1977/4885KMO 3655/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MKNK1 2453/4885MKNK2 1977/4885KMO 3655/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MKNK1 2453/4885MKNK2 1977/4885KMO 3655/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MKNK1 2453/4885MKNK2 1977/4885KMO 3655/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | MKNK1 2453/4885MKNK2 1977/4885KMO 3655/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | MKNK1 2453/4885MKNK2 1977/4885KMO 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.